235 related articles for article (PubMed ID: 36130755)
21. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
Alberici F; Jayne DR
Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
24. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Delestre F; Charles P; Karras A; Pagnoux C; Néel A; Cohen P; Aumaître O; Faguer S; Gobert P; Maurier F; Samson M; Godmer P; Bonnotte B; Cottin V; Hanrotel-Saliou C; Le Gallou T; Carron PL; Desmurs-Clavel H; Direz G; Jourde-Chiche N; Lifermann F; Martin-Silva N; Pugnet G; Quéméneur T; Matignon M; Benhamou Y; Daugas E; Lazaro E; Limal N; Ducret M; Huart A; Viallard JF; Hachulla E; Perrodeau E; Puechal X; Guillevin L; Porcher R; Terrier B;
Ann Rheum Dis; 2024 Jan; 83(2):233-241. PubMed ID: 37918894
[TBL] [Abstract][Full Text] [Related]
25. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
[No Abstract] [Full Text] [Related]
26. Rituximab in ANCA-Associated Vasculitis.
Hassan RI; Gaffo AL
Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
[TBL] [Abstract][Full Text] [Related]
28. Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?
Morel P; Karras A; Porcher R; Belenfant X; Audard V; Rafat C; Hanouna G; Beaudreuil S; Vilain C; Hummel A; Terrier B; Pillebout E; Groh M; Jouenne R; Dhote R; Fain O; Ponsoye M; Noel N; Limal N; Puéchal X; Le Jeunne C; Guillevin L; Mouthon L; Régent A
Rheumatology (Oxford); 2022 Oct; 61(10):4056-4064. PubMed ID: 35108368
[TBL] [Abstract][Full Text] [Related]
29. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial.
Zonozi R; Cortazar FB; Jeyabalan A; Sauvage G; Nithagon P; Huizenga NR; Rosenthal JM; Sipilief A; Cosgrove K; Laliberte KA; Rhee EP; Pendergraft WF; Niles JL
Ann Rheum Dis; 2024 Feb; 83(3):351-359. PubMed ID: 38123922
[TBL] [Abstract][Full Text] [Related]
30. Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.
Roccatello D; Sciascia S; Murgia S; Quattrocchio G; Ferro M; De Simone E; Naretto C; Barreca A; Sammartino A; Rossi D; Fenoglio R
Front Immunol; 2022; 13():777134. PubMed ID: 35401565
[TBL] [Abstract][Full Text] [Related]
31. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
32. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
34. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and safety of rituximab, mycophenolate, and cyclophosphamide in active antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2021 Oct; 59(10):645-653. PubMed ID: 34338191
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.
Liu L; Lu H; Zou G; Wang H; Li J; Yang Y; Zhang J; Wang X; Li W; Zhuo L
BMC Nephrol; 2023 Feb; 24(1):28. PubMed ID: 36755215
[TBL] [Abstract][Full Text] [Related]
37. Rituximab resistance at 3months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients.
Machet T; Quémeneur T; Ledoult E; Mesbah R; Lebas C; Hachulla E; Pokeerbux MR
Joint Bone Spine; 2023 Sep; 90(5):105591. PubMed ID: 37230162
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2022 Feb; 60(2):97-105. PubMed ID: 34622770
[TBL] [Abstract][Full Text] [Related]
39. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.
Gérard M; de Boysson H; Morello R; Martin-Silva N; Leroux AC; Dumont A; Maigné G; Boutemy J; Khoy K; Mariotte D; Lobbedez T; Aouba A; Deshayes S
Scand J Rheumatol; 2023 Mar; 52(2):161-173. PubMed ID: 35048797
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
